2020
A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer
Krop I, Abramson V, Colleoni M, Traina T, Holmes F, Garcia-Estevez L, Hart L, Awada A, Zamagni C, Morris PG, Schwartzberg L, Chan S, Gucalp A, Biganzoli L, Steinberg J, Sica L, Trudeau M, Markova D, Tarazi J, Zhu Z, O'Brien T, Kelly C, Winer E, Yardley D. A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer. Clinical Cancer Research 2020, 26: 6149-6157. PMID: 32988969, DOI: 10.1158/1078-0432.ccr-20-1693.Peer-Reviewed Original ResearchConceptsProgression-free survivalHormone receptor-positive breast cancerReceptor-positive breast cancerPhase II trialEndocrine therapyBreast cancerII trialAR mRNACohort 1Higher AR mRNA levelsLower ESR1 mRNA levelsET-naïve patientsGrade adverse eventsPrior endocrine therapyMetastatic breast cancerAndrogen receptor inhibitorMRNA levelsAR mRNA levelsESR1 mRNA levelsEnzalutamide armITT populationTreat populationAdvanced diseasePrimary endpointAdverse events
2018
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, Láng I, Gómez HL, Tondini C, Ciruelos E, Burstein HJ, Bonnefoi HR, Bellet M, Martino S, Geyer CE, Goetz MP, Stearns V, Pinotti G, Puglisi F, Spazzapan S, Climent MA, Pavesi L, Ruhstaller T, Davidson NE, Coleman R, Debled M, Buchholz S, Ingle JN, Winer EP, Maibach R, Rabaglio-Poretti M, Ruepp B, Di Leo A, Coates AS, Gelber RD, Goldhirsch A, Regan MM. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. New England Journal Of Medicine 2018, 379: 122-137. PMID: 29863451, PMCID: PMC6193457, DOI: 10.1056/nejmoa1803164.Peer-Reviewed Original ResearchConceptsTamoxifen plus ovarian suppressionTamoxifen-alone groupOvarian suppressionPremenopausal womenBreast cancerAdverse eventsOverall survivalDisease-free survival ratesOvarian Function TrialYears of tamoxifenAdjuvant endocrine therapyHigher adverse eventsReceipt of chemotherapyPremenopausal breast cancerLow recurrence rateAromatase inhibitor exemestaneUse of exemestaneSuppression groupExemestane TrialDistant recurrenceEndocrine therapyRecurrence rateGrade 3ExemestaneTamoxifen
2017
Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance)
Ellis MJ, Suman VJ, Hoog J, Goncalves R, Sanati S, Creighton CJ, DeSchryver K, Crouch E, Brink A, Watson M, Luo J, Tao Y, Barnes M, Dowsett M, Budd GT, Winer E, Silverman P, Esserman L, Carey L, X. C, Unzeitig G, Pluard T, Whitworth P, Babiera G, Guenther JM, Dayao Z, Ota D, Leitch M, Olson JA, Allred DC, Hunt K. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance). Journal Of Clinical Oncology 2017, 35: jco.2016.69.440. PMID: 28045625, PMCID: PMC5455353, DOI: 10.1200/jco.2016.69.4406.Peer-Reviewed Original ResearchMeSH KeywordsAgedAnastrozoleAndrostadienesAntineoplastic Combined Chemotherapy ProtocolsAromatase InhibitorsBreast NeoplasmsClinical Decision-MakingFemaleFollow-Up StudiesHumansKi-67 AntigenLetrozoleMiddle AgedMitotic IndexNeoadjuvant TherapyNeoplasm MetastasisNeoplasm Recurrence, LocalNeoplasm StagingNitrilesPredictive Value of TestsPrognosisProportional Hazards ModelsReceptors, EstrogenReceptors, ProgesteroneSurvival RateTranscriptomeTriazolesConceptsPreoperative endocrine prognostic indexBreast cancerNeoadjuvant chemotherapyAmerican CollegeEstrogen receptor-positive primary breast cancerNeoadjuvant aromatase inhibitor therapyPathologic complete response rateER-positive breast cancerAromatase inhibitor therapyComplete response rateER-positive tumorsPrimary breast cancerRisk of relapseAromatase inhibitor treatmentKi67 proliferation indexEndocrine monotherapyNeoadjuvant AIsAI therapyPCR ratePostmenopausal womenInhibitor therapyCox modelingOptimal therapyPrognostic indexRelapse risk
2016
Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial
Bartlett JM, Christiansen J, Gustavson M, Rimm DL, Piper T, van de Velde CJ, Hasenburg A, Kieback DG, Putter H, Markopoulos CJ, Dirix LY, Seynaeve C, Rea DW. Validation of the IHC4 Breast Cancer Prognostic Algorithm Using Multiple Approaches on the Multinational TEAM Clinical Trial. Archives Of Pathology & Laboratory Medicine 2016, 140: 66-74. PMID: 26717057, DOI: 10.5858/arpa.2014-0599-oa.Peer-Reviewed Original ResearchConceptsHazard ratioBreast cancerResidual riskMultivariate Cox proportional hazardsDistant recurrence-free survivalClinical prognostic factorsEarly breast cancerRecurrence-free survivalSignificant prognostic valueCox proportional hazardsHER2/neuIHC4 scoreHormone therapyNodal statusTrial cohortPrognostic factorsPrognostic valueClinical trialsKi-67Proportional hazardsMultivariate analysisTEAM trialBiomarker expressionQuantitative immunofluorescenceResidual risk assessment
2015
Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer
Aktas B, Sorkin M, Pusztai L, Hofstatter EW. Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer. European Journal Of Cancer Prevention 2015, 25: 3-8. PMID: 25642790, PMCID: PMC4885537, DOI: 10.1097/cej.0000000000000124.Peer-Reviewed Original ResearchConceptsCancer prevention clinicSelective estrogen receptor modulatorsPostmenopausal womenEstrogen receptor modulatorsChemoprevention uptakePrevention clinicReceptor modulatorsBreast cancer chemopreventionRetrospective chart reviewSerious side effectsChemoprevention medicationsChemopreventive optionChart reviewMean ageAromatase inhibitorsBreast cancerBone densityStudy populationCancer chemopreventionGeneral populationExemestaneSide effectsChemopreventionClinicWomenA network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer
Generali D, Venturini S, Rognoni C, Ciani O, Pusztai L, Loi S, Jerusalem G, Bottini A, Tarricone R. A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer. Breast Cancer Research And Treatment 2015, 152: 95-117. PMID: 26044370, DOI: 10.1007/s10549-015-3453-9.Peer-Reviewed Original ResearchConceptsProgression-free survivalMetastatic breast cancerHazard ratioMegestrol acetateResponse rateBreast cancerEstrogen receptor-positive metastatic breast cancerPFS/TTPSecond-line therapySecond-line treatmentToxicity of chemotherapyOverall response rateBetter response rateCapecitabineStandard pairwiseTamoxifenSunitinibChemotherapyTTP differenceMultiple treatmentsNMAIndividual studiesEverolimusExemestaneCancerRapid depot-specific activation of adipocyte precursor cells at the onset of obesity
Jeffery E, Church CD, Holtrup B, Colman L, Rodeheffer MS. Rapid depot-specific activation of adipocyte precursor cells at the onset of obesity. Nature Cell Biology 2015, 17: 376-385. PMID: 25730471, PMCID: PMC4380653, DOI: 10.1038/ncb3122.Peer-Reviewed Original ResearchMeSH KeywordsAdipocytes, WhiteAdipogenesisAdipose Tissue, WhiteAndrostadienesAnimalsCell ProliferationDiet, High-FatEatingMaleMiceMice, Inbred C57BLMice, KnockoutObesityPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsProto-Oncogene Proteins c-aktRandom AllocationTamoxifenWortmanninConceptsWhite adipose tissueAdipocyte precursorsMolecular mechanismsWAT growthNew adipocytesHigh-fat diet feedingCharacteristics of obesityOnset of obesityDistinct molecular mechanismsActivation of adipogenesisAdipocyte precursor cellsWAT massVisceral depotsDiet feedingMale miceAdipose tissueObesityAkt2 pathwayMature adipocytesPrecursor cellsAdipogenesisAdipocytesExcessive accumulationMiceActivation
2014
Adjuvant Ovarian Suppression in Premenopausal Breast Cancer
Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD. Adjuvant Ovarian Suppression in Premenopausal Breast Cancer. New England Journal Of Medicine 2014, 372: 436-446. PMID: 25495490, PMCID: PMC4341825, DOI: 10.1056/nejmoa1412379.Peer-Reviewed Original ResearchConceptsTamoxifen plus ovarian suppressionOvarian suppressionRate of freedomBreast cancerTamoxifen groupPremenopausal womenPrimary analysisDisease-free survival ratesPositive early breast cancerAdjuvant ovarian suppressionNonreceipt of chemotherapyYears of tamoxifenDisease-free survivalPremenopausal breast cancerEarly breast cancerOvarian estrogen productionOverall study populationSuppression groupGreater treatment effectUse of exemestaneAdjuvant chemotherapyPrior chemotherapyMost recurrencesPrognostic factorsPrior receiptAdjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA. Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer. New England Journal Of Medicine 2014, 371: 107-118. PMID: 24881463, PMCID: PMC4175521, DOI: 10.1056/nejmoa1404037.Peer-Reviewed Original ResearchMeSH KeywordsAdultAndrostadienesAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsAromatase InhibitorsBreast NeoplasmsChemotherapy, AdjuvantDisease-Free SurvivalEstradiolFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMastectomyMiddle AgedOsteoporosisPremenopauseQuality of LifeTamoxifenTriptorelin PamoateConceptsPositive early breast cancerEarly breast cancerOvarian suppressionBreast cancerPostmenopausal womenPremenopausal womenTamoxifen plus ovarian suppressionSuppression groupRate of freedomDisease-free survivalPhase 3 trialPremenopausal breast cancerOvarian estrogen productionPositive breast cancerAromatase inhibitor exemestaneAdjuvant exemestaneOvarian irradiationAdjuvant therapyAdjuvant treatmentAdverse eventsOverall survivalEstrogen productionAromatase inhibitorsGrade 3Primary analysis
2012
Mechanical stress-activated integrin α5β1 induces opening of connexin 43 hemichannels
Batra N, Burra S, Siller-Jackson AJ, Gu S, Xia X, Weber GF, DeSimone D, Bonewald LF, Lafer EM, Sprague E, Schwartz MA, Jiang JX. Mechanical stress-activated integrin α5β1 induces opening of connexin 43 hemichannels. Proceedings Of The National Academy Of Sciences Of The United States Of America 2012, 109: 3359-3364. PMID: 22331870, PMCID: PMC3295295, DOI: 10.1073/pnas.1115967109.Peer-Reviewed Original ResearchMeSH KeywordsAndrostadienesAnimalsCell LineChromonesConnexin 43Extracellular Matrix ProteinsFibronectinsImmunomagnetic SeparationIntegrin alpha5beta1MiceMorpholinesOsteocytesPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsProtein Interaction MappingRNA, Small InterferingStress, MechanicalWortmannin
2011
Phase II Trial of Neoadjuvant Exemestane in Combination With Celecoxib in Postmenopausal Women Who Have Breast Cancer
Lustberg M, Povoski S, Zhao W, Ziegler R, Sugimoto Y, Ruppert A, Lehman A, Shiels D, Mrozek E, Ramaswamy B, Layman R, Brueggemeier R, Shapiro C. Phase II Trial of Neoadjuvant Exemestane in Combination With Celecoxib in Postmenopausal Women Who Have Breast Cancer. Clinical Breast Cancer 2011, 11: 221-227. PMID: 21729671, PMCID: PMC3440773, DOI: 10.1016/j.clbc.2011.03.022.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAndrostadienesAntineoplastic AgentsBreast NeoplasmsCarcinoma, LobularCelecoxibCyclooxygenase 2Cyclooxygenase 2 InhibitorsDrug Therapy, CombinationFemaleFollow-Up StudiesHumansImmunoenzyme TechniquesLymphatic MetastasisMiddle AgedNeoadjuvant TherapyNeoplasm InvasivenessNeoplasm Recurrence, LocalNeoplasm StagingPostmenopausePyrazolesReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneSulfonamidesSurvival RateTreatment OutcomeConceptsPathological complete responsePhase II trialEstrogen receptorKi-67Neoadjuvant exemestaneII trialPostmenopausal womenCOX-2Breast cancerDefinitive breast cancer surgeryCOX-2 inhibitor celecoxibSerious cardiac eventsAnti-tumor responseBreast cancer surgeryAddition of celecoxibCOX-2 expressionMajority of womenStable diseaseCardiac eventsPartial responseComplete responseCancer surgeryCore biopsyAromatase inhibitorsHER-2
2009
A Comparative Study of Exemestane Versus Anastrozole in Patients with Postmenopausal Breast Cancer with Visceral Metastases
Campos SM, Guastalla JP, Subar M, Abreu P, Winer EP, Cameron DA. A Comparative Study of Exemestane Versus Anastrozole in Patients with Postmenopausal Breast Cancer with Visceral Metastases. Clinical Breast Cancer 2009, 9: 39-44. PMID: 19299239, DOI: 10.3816/cbc.2009.n.007.Peer-Reviewed Original ResearchConceptsPostmenopausal breast cancerBreast cancer metastasisBreast cancerPostmenopausal patientsVisceral metastasesAdverse eventsObjective responseVisceral sitesVisceral lesionsClinical benefitTreatment-related adverse eventsCancer metastasisAromatase inhibitor studiesAdvanced breast cancerResponse Evaluation CriteriaExemestane groupEndocrine therapyPostmenopausal womenPrimary endpointSecondary endpointsMedian survivalOverall survivalSuch patientsTreat analysisStudy closure
2007
Cost-Effectiveness of Switching to Exemestane after 2 to 3 Years of Therapy with Tamoxifen in Postmenopausal Women with Early-Stage Breast Cancer
Thompson D, Taylor DC, Montoya EL, Winer EP, Jones SE, Weinstein MC. Cost-Effectiveness of Switching to Exemestane after 2 to 3 Years of Therapy with Tamoxifen in Postmenopausal Women with Early-Stage Breast Cancer. Value In Health 2007, 10: 367-376. PMID: 17888101, DOI: 10.1111/j.1524-4733.2007.00190.x.Peer-Reviewed Original ResearchMeSH KeywordsAgedAndrostadienesAntineoplastic ProtocolsAromatase InhibitorsBreast NeoplasmsCost-Benefit AnalysisDrug Administration ScheduleFemaleForecastingHumansMarkov ChainsMiddle AgedNeoplasm Recurrence, LocalPostmenopauseQuality-Adjusted Life YearsSEER ProgramSelective Estrogen Receptor ModulatorsTamoxifenConceptsIntergroup Exemestane StudyDisease-free survivalDisease-related eventsTreatment strategiesEarly-stage breast cancer patientsEarly-stage breast cancerProlongs disease-free survivalCost-effective treatment strategyIncremental cost-effectiveness ratioYears of tamoxifenYears of therapyBreast cancer patientsSEER-Medicare dataBreast cancer statusLifetime medical care costsMedical care costsCost-effectiveness ratioTamoxifen therapyPostmenopausal womenRecurrence rateCancer careCancer patientsPatient transitionsAromatase inhibitorsBreast cancerLigand‐dependent responses of the ErbB signaling network: experimental and modeling analyses
Birtwistle MR, Hatakeyama M, Yumoto N, Ogunnaike BA, Hoek JB, Kholodenko BN. Ligand‐dependent responses of the ErbB signaling network: experimental and modeling analyses. Molecular Systems Biology 2007, 3: msb4100188. PMID: 18004277, PMCID: PMC2132449, DOI: 10.1038/msb4100188.Peer-Reviewed Original ResearchMeSH KeywordsAndrostadienesButadienesCell Line, TumorCell MembraneDimerizationEnzyme ActivationEpidermal Growth FactorExtracellular Signal-Regulated MAP KinasesFeedback, PhysiologicalHumansLigandsModels, BiologicalNeuregulin-1NitrilesPhosphoinositide-3 Kinase InhibitorsPhosphorylationProtein Structure, TertiaryProto-Oncogene Proteins c-aktReceptor Protein-Tyrosine KinasesReproducibility of ResultsSignal TransductionWortmanninConceptsEpidermal growth factorERK activityEGF-induced signalingMultiple human cancersPhosphoinositol-3 kinaseLigand-dependent responsesSustained signalingERK activationDownstream proteinsAkt activationInhibitor U0126Major regulatorHuman cancersErbB receptorsLigand dosesHeregulinErbBKinaseSignalingGrowth factorActivationKey roleU0126AktRegulatorPI3 Kinase Dependent Stimulation of Gastric Acid Secretion by Dexamethasone
Lang P, Schniepp R, Kirchhoff P, Socrates T, Sidani S, Geibel J. PI3 Kinase Dependent Stimulation of Gastric Acid Secretion by Dexamethasone. Cellular Physiology And Biochemistry 2007, 20: 527-534. PMID: 17762179, DOI: 10.1159/000107536.Peer-Reviewed Original ResearchMeSH KeywordsAndrostadienesAnimalsCimetidineDexamethasoneGastric AcidGastric MucosaH(+)-K(+)-Exchanging ATPaseMaleNitrobenzoatesPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsPotassium Channel BlockersProtein Kinase InhibitorsProton Pump InhibitorsRatsRats, Sprague-DawleyStaurosporineWortmanninConceptsGastric acid secretionProtein kinase inhibitor staurosporinePI3-kinase inhibitor wortmanninAcid secretionKinase inhibitor staurosporineKinase inhibitor wortmanninPI3-kinase pathwayPeptic ulcerDexamethasone effectApical Cl- channelsKinase pathwayInhibitor wortmanninInhibitor staurosporineExcessive gastric acid secretionProton extrusionATPase inhibitor omeprazoleCl- channel blockers NPPBCl- channelsChannel blocker NPPBDependent stimulationDexamethasone injectionVivo pretreatmentInhibitor omeprazoleParietal cellsSecretion
2006
Activated c-Fms recruits Vav and Rac during CSF-1-induced cytoskeletal remodeling and spreading in osteoclasts
Sakai H, Chen Y, Itokawa T, Yu KP, Zhu ML, Insogna K. Activated c-Fms recruits Vav and Rac during CSF-1-induced cytoskeletal remodeling and spreading in osteoclasts. Bone 2006, 39: 1290-1301. PMID: 16950670, DOI: 10.1016/j.bone.2006.06.012.Peer-Reviewed Original ResearchMeSH KeywordsActinsAndrostadienesAnimalsBiological Transport, Activecdc42 GTP-Binding ProteinCells, CulturedCytoskeletonEnzyme InhibitorsGuanosine TriphosphateHumansMacrophage Colony-Stimulating FactorMiceModels, BiologicalOsteoclastsPhosphoinositide-3 Kinase InhibitorsProtein BindingProto-Oncogene Proteins c-vavPseudopodiarac GTP-Binding ProteinsRatsReceptor, Macrophage Colony-Stimulating FactorRecombinant ProteinsSignal TransductionWortmanninConceptsCSF-1GEF activityCytoskeletal remodelingGTPase activityAssociation of VavC-fmsRac GTPase activityDominant negative Cdc42Dominant-negative RacCSF-1 receptorInhibitors of PI3CSF-1 treatmentTarget GTPaseActive RacExchange factorActive Cdc42Actin reorganizationLamellipodia formationPhosphotyrosine contentC-SrcPlasma membraneInhibitor of RhoARapid translocationVavRac translocationVoltage-gated potassium channel Kv1.3 regulates GLUT4 trafficking to the plasma membrane via a Ca2+-dependent mechanism
Li Y, Wang P, Xu J, Desir GV. Voltage-gated potassium channel Kv1.3 regulates GLUT4 trafficking to the plasma membrane via a Ca2+-dependent mechanism. American Journal Of Physiology - Cell Physiology 2006, 290: c345-c351. PMID: 16403947, DOI: 10.1152/ajpcell.00091.2005.Peer-Reviewed Original ResearchConceptsPlasma membraneKv1.3 channel activityAmount of GLUT4GLUT4 protein translocationInsulin sensitivityChannel activityChannel inhibitionAddition of wortmanninGLUT4 traffickingInsulin-dependent pathwayProtein translocationPeripheral insulin sensitivityVoltage-gated potassium channel Kv1.3GLUT4 translocationPotassium channel Kv1.3Gene inactivationInsulin-sensitive tissuesGLUT4 proteinKv1.3 inhibitionGlucose transportPsora-4Channel Kv1.3Adipose tissueBody weightPharmacological inhibition
2005
Regulation of CHK2 by DNA-dependent Protein Kinase*
Li J, Stern DF. Regulation of CHK2 by DNA-dependent Protein Kinase*. Journal Of Biological Chemistry 2005, 280: 12041-12050. PMID: 15668230, DOI: 10.1074/jbc.m412445200.Peer-Reviewed Original ResearchMeSH KeywordsAndrostadienesAntigens, NuclearAtaxia Telangiectasia Mutated ProteinsCell Cycle ProteinsCells, CulturedCheckpoint Kinase 2DNADNA DamageDNA-Activated Protein KinaseDNA-Binding ProteinsEnzyme ActivationHumansKu AutoantigenNuclear ProteinsPhosphorylationProtein Serine-Threonine KinasesTumor Suppressor ProteinsWortmanninConceptsActivation of Chk2DNA-PKChk2 phosphorylationDNA damageDNA-Dependent Protein Kinase Catalytic SubunitProtein Kinase Catalytic SubunitDNA-dependent protein kinaseFunctional DNA-PKRegulation of Chk2Kinase catalytic subunitRegulation of DNAChk2 kinase activityATM-deficient cellsDiverse cellular responsesKinase inhibitor wortmanninATM-defective cellsChk2 activationExposure of cellsCatalytic subunitProtein kinaseKinase activityChk2Inhibitor wortmanninRabbit reticulocytesCellular responses
2004
Strain-induced vascular endothelial cell proliferation requires PI3K-dependent mTOR-4E-BP1 signal pathway
Li W, Sumpio BE. Strain-induced vascular endothelial cell proliferation requires PI3K-dependent mTOR-4E-BP1 signal pathway. AJP Heart And Circulatory Physiology 2004, 288: h1591-h1597. PMID: 15591103, DOI: 10.1152/ajpheart.00382.2004.Peer-Reviewed Original ResearchMeSH Keywords3-Phosphoinositide-Dependent Protein KinasesAndrostadienesAnimalsAntibiotics, AntineoplasticAortaCarrier ProteinsCattleCell DivisionCells, CulturedChromonesEndothelium, VascularEnzyme InhibitorsFlavonoidsMitogen-Activated Protein Kinase 1Mitogen-Activated Protein Kinase 3MorpholinesPhosphatidylinositol 3-KinasesPhosphodiesterase InhibitorsPhosphoinositide-3 Kinase InhibitorsPhosphoproteinsPhosphorylationProtein KinasesProtein Serine-Threonine KinasesProto-Oncogene ProteinsProto-Oncogene Proteins c-aktRibosomal Protein S6 KinasesSignal TransductionSirolimusTOR Serine-Threonine KinasesWortmanninConceptsVascular endothelial cell proliferationEndothelial cell proliferationStrain-induced activationSignal pathwayEC proliferationPD 98059Cell proliferationPI3K inhibitor wortmanninPI3K inhibitorsCycles/minExtracellular signal-regulated kinases 1Inhibitor PD 98059MTOR pathwaySignal-regulated kinases 1Bovine aortic ECsMammalian targetMTOR-4EK inhibitorsEukaryotic initiation factor 4EAortic ECsInitiation factor 4EMEK1 inhibitor PD 98059K activationProliferationRapamycinLaryngeal Findings in Users of Combination Corticosteroid and Bronchodilator Therapy
Mirza N, Schwartz S, Antin‐Ozerkis D. Laryngeal Findings in Users of Combination Corticosteroid and Bronchodilator Therapy. The Laryngoscope 2004, 114: 1566-1569. PMID: 15475783, DOI: 10.1097/00005537-200409000-00012.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAdrenergic beta-AgonistsAdultAgedAged, 80 and overAlbuterolAndrostadienesAsthmaBronchodilator AgentsDilatation, PathologicDrug Therapy, CombinationFemaleFluticasoneHemorrhageHumansLaryngeal DiseasesLaryngeal EdemaLaryngeal NeoplasmsLaryngitisLaryngoscopyLarynxLeukoplakiaMaleMiddle AgedPrecancerous ConditionsSalmeterol XinafoateVocal CordsVoice DisordersConceptsDry powder inhalerUse of inhalersLaryngeal findingsBronchodilator therapyMaintenance therapyLaryngeal irritationCombination therapyCombination corticosteroidSurface mucosaPatients meeting inclusion criteriaVoice changesConsecutive patients meeting inclusion criteriaProton pump inhibitorsAreas of hyperemiaMeeting inclusion criteriaDPI therapyGastroesophageal refluxAsthma medicationsRetrospective reviewUpper airwayPump inhibitorsLaryngeal mucosaVoice centerPatient educationInclusion criteria
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply